New drug cocktail aims to boost myeloma remission before transplant
NCT ID NCT05199311
First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This study tests a combination of three drugs—carfilzomib, iberdomide, and dexamethasone (KID)—in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this mix is safe and improves remission rates before transplant. About 66 participants will be enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib, iberdomide, and dexamethasone (KID combination)
What this could lead to
If successful, this could offer a more effective initial treatment for newly diagnosed multiple myeloma, potentially improving remission rates before stem cell transplant.
What could go wrong
This is an early-phase trial with only 66 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not a cure—patients will still need ongoing management.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.